- Home
- NXGL vs PHIO Comparison
NXGL vs PHIO Comparison
Compare NXGL & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | PHIO |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 12.3M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NXGL | PHIO |
|---|---|---|
| Price | $1.18 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 41.3K | ★ 7.0M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $42.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $0.81 |
| 52 Week High | $3.36 | $4.19 |
Technical Indicators
Market Signals| Indicator | NXGL | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 45.37 |
| Support Level | $1.18 | $0.96 |
| Resistance Level | $1.76 | $1.21 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 14.71 | 19.42 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.